Clinical Trials Logo

Relapsed Acute Myeloid Leukemia clinical trials

View clinical trials related to Relapsed Acute Myeloid Leukemia.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05362942 Not yet recruiting - Clinical trials for Refractory Acute Myeloid Leukemia

Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia

Start date: May 1, 2022
Phase: Phase 2
Study type: Interventional

Although studies are ongoing to evaluate the efficiency and safety of venetoclax-based therapy, alone or in combination with hypomethylation agent or low-dose cytarabine, in relapsed/refractory acute myeloid leukemia, data are scarce and heterogenous. In this study, the investigators aimed to assess safety and response to a new venetoclax-based triple-drug combination regimen (venetoclax + hypomethylation agent + low-dose cytarabine) in acute myeloid leukemia patients who had relapsed/refractory disease or positive minimal residual disease.